Q2 Cannabis Bankers’ Quarterly: Cannabis Lending After Rescheduling: What Changes, What Matters, What's Next?
- 4 days ago
- 1 min read
Updated: 1 day ago
Description
Medical cannabis rescheduling could significantly reshape the financial landscape for cannabis operators and the institutions that serve them, but major questions remain around taxes, underwriting, legal protections, and risk management.
This webinar features a timely discussion with cannabis tax and risk experts as they break down what this moment means for bankers. In particular, we will discuss how changes tied to the Section 280E tax code may impact operator cash flow, credit profiles, and overall lending risk. Panelists share why medical cannabis businesses may present a different risk profile going forward, what lenders should be watching for in both medical and adult-use operators, and how to assess borrowers in a rapidly evolving environment.
Key Topics
What rescheduling means for 280E and near-term tax implications
How shifting tax treatment could impact operator cash flow and debt service capacity
Key credit risk considerations for cannabis lending programs
Red flags and underwriting considerations across medical vs. adult-use operators
Questions bankers should be asking now—before extending or expanding credit
Speakers:
Jill Scher, Managing Director, Tax & Business Services Division, CBIZ
Scott Moskol, Partner and Co-Chair, Cannabis Practice, Blank Rome LLP
Moderated by Tony Repanich, President and CEO, Shield Compliance
Designed specifically for financial institutions serving or considering serving licensed cannabis businesses, this webinar delivers practical, actionable insights to help you evaluate risk, identify opportunity, and make more informed lending decisions. Learn More
Presented by Shield Compliance the Association for Cannabis Banking
